WG
ALLO icon

Winton Group’s Allogene Therapeutics ALLO Stock Holding History

Winton Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
158,160
+36,960
+30% +$81.2K 0.01% 858
2026
Q1 		$296K Buy
+121,200
New +$243K 0.01% 866
2023
Q2 		– Sell
-37,255
Closed -$184K – 768
2023
Q1 		$184K Buy
37,255
+2,251
+6% +$14.4K 0.01% 912
2022
Q4 		$220K Buy
35,004
+1,722
+5% +$15.9K 0.01% 855
2022
Q3 		$359K Sell
33,282
-5,366
-14% -$72.9K 0.02% 737
2022
Q2 		$441K Buy
38,648
+8,178
+27% +$72.6K 0.02% 722
2022
Q1 		$278K Buy
30,470
+5,911
+24% +$61.6K 0.01% 836
2021
Q4 		$366K Sell
24,559
-5,453
-18% -$96.2K 0.02% 772
2021
Q3 		$771K Sell
30,012
-1,654
-5% -$39.3K 0.04% 635
2021
Q2 		$826K Buy
31,666
+11,757
+59% +$335K 0.04% 638
2021
Q1 		$703K Sell
19,909
-2,535
-11% -$85.5K 0.04% 680
2020
Q4 		$566K Sell
22,444
-66,719
-75% -$2.17M 0.04% 727
2020
Q3 		$3.36M Buy
89,163
+35,123
+65% +$1.32M 0.11% 277
2020
Q2 		$2.31M Buy
54,040
+5,832
+12% +$211K 0.06% 582
2020
Q1 		$937K Buy
48,208
+6,634
+16% +$158K 0.02% 823
2019
Q4 		$1.08M Buy
+41,574
New +$1.15M 0.02% 1040

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Winton Group's ALLO Position: Q2 2026 in Review

Winton Group increased its Allogene Therapeutics (ALLO) stake by 30% in Q2 2026, buying an estimated $81.2K and bringing the position to 158,160 shares worth $329K. The position accounts for 0.01% of the portfolio, ranked #858.

Winton Group first reported a position in ALLO in Q4 2019 and has held it in 16 quarters since. The position peaked at $3.36M in Q3 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Winton Group held 158,160 shares of Allogene Therapeutics worth $329K as of Q2 2026.
  • Winton Group bought 36,960 Allogene Therapeutics shares in Q2 2026, an estimated $81.2K.
  • Allogene Therapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #858 holding.
  • Winton Group first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 16 quarters since.
  • Winton Group's Allogene Therapeutics position peaked at $3.36M in Q3 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.